GCM
ADCT icon

Graham Capital Management’s ADC Therapeutics ADCT Stock Holding History

Graham Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.2K Buy
+22,442
New +$88.5K ﹤0.01% 1059
2022
Q3 		– Sell
-12,992
Closed -$103K – 1040
2022
Q2 		$103K Buy
+12,992
New +$123K ﹤0.01% 957

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Graham Capital Management's ADCT Position: Q1 2026 in Review

Graham Capital Management opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 22,442 shares worth $84.2K. The stake represents ﹤0.01% of the portfolio and ranks #1059 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in ADCT as recently as Q2 2022.

Graham Capital Management first reported a position in ADCT in Q2 2022 and has held it in 2 quarters since. The position peaked at $103K in Q2 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Graham Capital Management held 22,442 shares of ADC Therapeutics worth $84.2K as of Q1 2026.
  • ADC Therapeutics was a new Graham Capital Management position in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1059 holding.
  • Graham Capital Management first reported a position in ADC Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • Graham Capital Management's ADC Therapeutics position peaked at $103K in Q2 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.